Results 71 to 80 of about 1,503 (160)

Effect of allopurinol and oxypurinol treatment on apoptosis in an experimental testicular torsion model. [PDF]

Ulus Travma Acil Cerrahi Derg
Bilaloglu E, Duman L, Erzurumlu Y, Ertunc O, Kart Y.   +4 more
europepmc   +1 more source

Interpretation of Pharmacometabolomics Results: Fingerprint of Drug Exposure or Confounder Effects? Insights from a Urinary Metabolomics Study with Voriconazole in Healthy Participants. [PDF]

Int J Mol Sci
Chobanyan-Jürgens K, Muhareb A, Niesert M, Scherkl C, Meid AD, Cannet C, Pituk D, Hoffmann GF, Stingl JC, Ziegler A, Blank A.   +10 more
europepmc   +1 more source

Single-cell-based identification of drug synergy with immunotherapy via tumor microenvironment remodeling. [PDF]

J Immunother Cancer
Wang Z, Hu J, Liu K, Xu J, Li J, Liu Y, Ma Q, Dong Y, Zhu Y, Zhang K, Wang D, Wang X, Wang S, Pan J, Jiang S, Wu J, Jiang W, Zhang L, Dang Y.   +18 more
europepmc   +1 more source

Successful Extended Allopurinol Desensitization in an Elderly Patient With Chronic Kidney Disease and Febuxostat Intolerance. [PDF]

Cureus
Ramesh R, Nagaraja V, Gonzalez-Estrada A.   +2 more
europepmc   +1 more source

The genetics of gout: translation into clinical practice. [PDF]

Ther Adv Musculoskelet Dis
Merriman TR, Rosas-Chavez F, Stamp LK.
europepmc   +1 more source

Population pharmacokinetics, pharmacodynamics and pharmacogenetics modelling of oxypurinol in Hmong adults with gout and/or hyperuricemia. [PDF]

Br J Clin Pharmacol, 2023
Wen YF, Brundage RC, Roman YM, Culhane-Pera KA, Straka RJ.   +4 more
europepmc   +1 more source

Targeting ryanodine receptors with allopurinol and xanthine derivatives for the treatment of cardiac and musculoskeletal weakness disorders. [PDF]

Proc Natl Acad Sci U S A
Miotto MC, Luna-Figueroa E, Tchagou C, Bahlouli L, Reiken S, Dridi H, Liu Y, Weninger G, Marks AR.   +8 more
europepmc   +1 more source

Dosing practices, pharmacokinetics, and effectiveness of allopurinol in gout patients receiving dialysis: a scoping review. [PDF]

J Nephrol
Kamel NA, Stokes MA, Wright DFB, Sud K, Tarafdar S, Castelino RL, Stocker SL.   +6 more
europepmc   +1 more source

Trichloroethylene 改变融合期内皮细胞一氧化氮和氧自由基的平衡

Zhongshan Daxue xuebao. Yixue kexue ban, 2004
【目的】Trichloroethylene(TRI)是一种与先天性心脏病发生有关的环境污染物,我们最近报道在分裂期的内皮细胞(EC)中,TRI可以通过减少热休克蛋白90(hsp90)与内皮一氧化氮合酶(eNOS)结合,从而抑制刺激状态下一氧化氮(NO)产生和增加刺激状态下eNOS依赖的超氧阴离子自由基()产生和抑制血管内皮生长因子刺激的内皮细胞分裂。但TRI在融合期EC中的影响仍未清楚。本实验目的是探讨TRI对融合期EC的影响。【方法】TRI5μmol/L预处理融合期EC ...
doaj  

FARFOOD: a database of potential interactions between food compounds and drugs. [PDF]

BioData Min
Nevado-Bulnes AM, Benitez DA, Cumplido-Laso G, Carvajal-González JM, Mulero-Navarro S, Román AC.   +5 more
europepmc   +1 more source